Clinical trial · Observational
The Therapeutic Effect of Immunotherapy in Patients With Advanced Lung Squamous Carcinoma
Exploration of the Treatment Trajectory and Drug Resistance Mechanism of Immunotherapy Combined With Chemotherapy in Patients With Advanced Lung Squamous Carcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this observational study is to investigate the treatment trajectory of immunotherapy in patients with squamous non-small cell lung cancer (sq-NSCLC). The primary objective is to identify potential indicators that can predict the efficacy of immunotherapy and explore strategies to prolong its effectiveness in sq-NSCLC patients. Biological specimens and medical imaging data will be collected from patients already receiving immunotherapy as a first-line treatment, and follow-up will be conducted to analyze prognosis based on different patterns.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Squamous Cell Lung Cancer | Lung Squamous Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Efficacy observation | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- label
- untreated sq-NSCLC patients
- description
- Patients diagnosed with sq-NSCLC for the first time
- interventionNames
- Other: Efficacy observation
- label
- sq-NSCLC patients treated with immunotherapy for -2-3 cycles
- description
- sq-NSCLC patients treated with immunotherapy combined with or without chemotherapy as first-line treatment for 2-3 cycles.
- interventionNames
- Other: Efficacy observation
- label
- sq-NSCLC patients receiving immunotherapy with poor efficacy
- description
- sq-NSCLC patients treated with immunotherapy combined with or without chemotherapy as first-line treatment and experience disease progression within six months.
- interventionNames
- Other: Efficacy observation
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosed with sq-NSCLC; * Receiving immunotherapy combined with or without chemotherapy as first-line treatment; * ≥ 18 years and ≤ 80 years old; * No previous treatment in the lungs or any other organ. Exclusion Criteria: * History of cancer treatment; * History of other malignant tumors; * Irregular treatment or poor compliance; * Incomplete clinical information or lost to follow-up.
References
Publications (0)
Data not yet available